Intensive Treat-to-Target Statin Therapy in High-Risk Japanese Patients With Hypercholesterolemia and Diabetic Retinopathy: Report of a Randomized Study.
Hiroshi ItohIssei KomuroMasahiro TakeuchiTakashi AkasakaHiroyuki DaidaYoshiki EgashiraHideo FujitaJitsuo HigakiKen-Ichi HirataShun IshibashiTakaaki IsshikiSadayoshi ItoAtsunori KashiwagiSatoshi KatoKazuo KitagawaMasafumi KitakazeTakanari KitazonoMasahiko KurabayashiKatsumi MiyauchiTomoaki MurakamiToyoaki MuroharaKoichi NodeSusumu OgawaYoshihiko SaitoYoshihiko SeinoTakashi ShigeedaShunya ShindoMasahiro SugawaraSeigo SugiyamaYasuo TerauchiHiroyuki TsutsuiKenji UeshimaKazunori UtsunomiyaMasakazu YamagishiTsutomu YamazakiShoei YoKoutaro YokoteKiyoshi YoshidaMichihiro YoshimuraNagahisa YoshimuraKazuwa NakaoRyozo Nagainull nullPublished in: Diabetes care (2018)
We found no significant decrease in CV events or CV-associated deaths with intensive therapy, possibly because our between-group difference of LDL-C was lower than expected (27.7 mg/dL at 36 months of treatment). The potential benefit of achieving LDL-C <70 mg/dL in a treat-to-target strategy in high-risk patients deserves further investigation.
Keyphrases
- diabetic retinopathy
- end stage renal disease
- low density lipoprotein
- ejection fraction
- newly diagnosed
- chronic kidney disease
- cardiovascular disease
- peritoneal dialysis
- coronary artery disease
- cardiovascular events
- type diabetes
- climate change
- mesenchymal stem cells
- replacement therapy
- smoking cessation
- human health